Physician profile
Fernando Lopez
NPI 1659391951
$17,710.46
in general payments reported to CMS, 2019-2025
26 companies · $3,622 in 2025
The $3,622 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,795 · 2020: $1,060 · 2021: $2,059 · 2022: $3,278 · 2023: $2,698 · 2024: $3,200 · 2025: $3,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,519.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,382.88 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $2,061.08 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $2,012.63 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,750.12 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,710.67 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,015.30 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $829.53 | 2024-2025 | Fanapt |
| Allergan, INC. | $796.04 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $768.74 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $754.99 | 2019-2022 | |
| Indivior INC. | $583.26 | 2021-2025 | Perseris, Sublocade |
| Axsome Therapeutics, INC. | $536.05 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $397.11 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $320.73 | 2021-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $157.17 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $139.80 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $112.07 | 2024 | Qelbree |
| Almatica Pharma LLC | $97.57 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $69.33 | 2021 | |
| Acadia Pharmaceuticals INC | $53.19 | 2019 | |
| Ironshore Pharmaceuticals INC. | $47.51 | 2023 | Jornay Pm |
| Eisai INC. | $43.82 | 2020-2022 | |
| Tris Pharma INC | $20.27 | 2023 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.73 | 2025 | Rejoyn |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.44 | 2025 | |
| Collegium Pharmaceutical, INC. | $15.43 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.